For decades, sodium restriction has been treated as a cornerstone of heart failure self-care—despite limited trial-quality evidence. In this episode of the Heart Failure Beat, Dr. Tariq Ahmad (Yale School of Medicine; Associate Editor, JACC: Heart Failure) joins hosts Michael Beasley, MD, and Priya Umapathi, MD, to unpack what we actually know about sodium targets in hospitalized and outpatient heart failure. They discuss why inpatient studies have been inconsistent, why a VA-commissioned review concluded sodium restriction for admitted HF patients is not supported, and how focusing on “dietary indiscretion” can distract from evidence-based priorities like GDMT. Dr. Ahmad also previews the pragmatic, EHR-embedded SOAR-AHF trial designed to compare regular vs low-sodium hospital diets and measure outcomes like length of stay and readmissions.
Listen below and subscribe: Apple Podcasts, Amazon Music, Spotify, Podcast Home
Tune into highlight clips on YouTube
References, Links and Disclosures
Dr. Ahmad reports receiving grants from Amgen, AstraZeneca, and Boehringer Ingelheim. He had received consulting fees from Novo Nordisk, Eli Lilly, Edwards Lifesciences, AstraZeneca, and Boehringer Ingelheim.
Ahmad, T. We Need to Stop Telling Heart Failure Patients to Restrict Their Salt Intake. J Am Coll Cardiol HF. 2025 Jan, 13 (1) 173–174. https://doi.org/10.1016/j.jchf.2024.10.011
Herrmann, J.J., Brunner-La Rocca, HP., Baltussen, L.E.H.J.M. et al. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Nat Med (2025). https://doi.org/10.1038/s41591-025-03628-4